Zurcher Kantonalbank (Zurich Cantonalbank) Biomarin Pharmaceutical Inc Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$33.8 Billion
Q1 2025

A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 208,455 shares of BMRN stock, worth $11.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

208,455

Previous 198,756 4.88%

Holding current value

$11.9 Million

Previous $13.1 Million 12.79%

% of portfolio

0.04%

Previous 0.04%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	BUY	$61.25 - $72.83 $594,063 - $706,378	9,699 Added 4.88%	208,455 $14.7 Million
Q4 2024 Feb 07, 2025	BUY	$61.93 - $70.49 $6.3 Million - $7.18 Million	101,794 Added 104.98%	198,756 $13.1 Million
Q3 2024 Nov 07, 2024	BUY	$69.02 - $93.84 $178,623 - $242,857	2,588 Added 2.74%	96,962 $6.82 Million
Q2 2024 Jul 29, 2024	BUY	$74.43 - $92.22 $132,336 - $163,967	1,778 Added 1.92%	94,374 $7.77 Million
Q1 2024 Apr 25, 2024	BUY	$83.81 - $99.0 $1.21 Million - $1.43 Million	14,486 Added 18.55%	92,596 $8.09 Million
Q4 2023 Jan 30, 2024	BUY	$76.22 - $98.51 $3.22 Million - $4.16 Million	42,250 Added 117.82%	78,110 $7.53 Million
Q3 2023 Oct 25, 2023	SELL	$85.07 - $94.48 $47,298 - $52,530	-556 Reduced 1.53%	35,860 $3.17 Million
Q2 2023 Aug 07, 2023	BUY	$86.68 - $100.3 $274,862 - $318,051	3,171 Added 9.54%	36,416 $3.16 Million
Q1 2023 May 08, 2023	SELL	$87.74 - $117.27 $5,352 - $7,153	-61 Reduced 0.18%	33,245 $3.23 Million
Q4 2022 Feb 01, 2023	SELL	$80.93 - $108.63 $37,146 - $49,861	-459 Reduced 1.36%	33,306 $3.45 Million
Q3 2022 Nov 09, 2022	BUY	$82.16 - $96.94 $329,625 - $388,923	4,012 Added 13.48%	33,765 $2.86 Million
Q2 2022 Aug 09, 2022	SELL	$71.48 - $86.85 $100,929 - $122,632	-1,412 Reduced 4.53%	29,753 $2.47 Million
Q1 2022 Apr 21, 2022	BUY	$74.28 - $92.69 $131,549 - $164,153	1,771 Added 6.03%	31,165 $2.4 Million
Q4 2021 Feb 01, 2022	SELL	$71.72 - $91.47 $1.06 Million - $1.35 Million	-14,733 Reduced 33.39%	29,394 $2.6 Million
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $135,408 - $154,786	-1,811 Reduced 3.94%	44,127 $3.41 Million
Q2 2021 Jul 30, 2021	BUY	$75.51 - $84.79 $18,953 - $21,282	251 Added 0.55%	45,938 $3.83 Million
Q1 2021 May 03, 2021	BUY	$74.73 - $90.69 $548,966 - $666,208	7,346 Added 19.16%	45,687 $3.45 Million
Q4 2020 Jan 28, 2021	BUY	$72.61 - $90.2 $70,649 - $87,764	973 Added 2.6%	38,341 $3.36 Million
Q3 2020 Nov 06, 2020	BUY	$71.87 - $131.03 $599,898 - $1.09 Million	8,347 Added 28.76%	37,368 $2.84 Million
Q2 2020 Jul 28, 2020	SELL	$79.55 - $124.22 $675,538 - $1.05 Million	-8,492 Reduced 22.64%	29,021 $3.58 Million
Q1 2020 May 06, 2020	BUY	$71.37 - $96.85 $189,059 - $256,555	2,649 Added 7.6%	37,513 $3.17 Million
Q2 2019 Jul 30, 2019	SELL	$80.35 - $93.9 $699,125 - $817,023	-8,701 Reduced 19.97%	34,864 $2.99 Million
Q1 2019 Apr 29, 2019	BUY	$84.2 - $98.62 $123,774 - $144,971	1,470 Added 3.49%	43,565 $3.87 Million
Q4 2018 Jan 25, 2019	BUY	$80.14 - $106.07 $418,090 - $553,367	5,217 Added 14.15%	42,095 $3.58 Million
Q3 2018 Nov 09, 2018	SELL	$93.92 - $105.72 $60,578 - $68,189	-645 Reduced 1.72%	36,878 $3.58 Million
Q1 2018 May 03, 2018	SELL	$77.67 - $92.63 $22,213 - $26,492	-286 Reduced 0.76%	37,523 $3.04 Million
Q4 2017 Jan 31, 2018	SELL	$80.76 - $95.13 $136,968 - $161,340	-1,696 Reduced 4.29%	37,809 $3.37 Million
Q3 2017 Nov 08, 2017	BUY	$80.6 - $94.95 $3.18 Million - $3.75 Million	39,505	39,505 $3.68 Million

Others Institutions Holding BMRN

# of Institutions

669

Shares Held

184M

Call Options Held

1.24M

Put Options Held

957K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.6B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account

Zurcher Kantonalbank (Zurich Cantonalbank) Biomarin Pharmaceutical Inc Transaction History